Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
about
Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?Distinct molecular subtypes of gastric cancer: from Laurén to molecular pathology.Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell.New therapeutic options opened by the molecular classification of gastric cancer.What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future PerspectivesEffect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure?
P2860
Q41344857-56BEC774-31DE-4089-8BAB-B6F0243D7731Q42693879-647FEE1C-7CB8-4FBB-AAEC-9D380D0A5F80Q47402625-807599F3-665E-4B8C-AD8B-8B265336B6FAQ47864236-5CC176F6-F1AE-46A4-A947-8FF90C135927Q49651740-5C991673-4522-434D-B7FC-996016504B98Q49961144-7A35E4C9-9FF6-49A2-B4A3-1AF9BB980004Q54970742-E2B4272B-C591-4388-9C1E-1360CF2FBED6Q55117181-2A59EC62-BDB4-4AC8-8801-BF24345A76E9Q55365203-2C2428A5-8B25-400F-88A6-106CF18BA13EQ55527185-E81B35D7-27B1-4ACC-849C-5C702A8CFFDAQ57159608-AD99E41C-A639-425A-854B-6E686F433603Q58555802-7F572062-32A3-4A8A-9B25-3F3068B9A38A
P2860
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effect of Fluorouracil, Leucov ...... ric Randomized Clinical Trial.
@en
type
label
Effect of Fluorouracil, Leucov ...... ric Randomized Clinical Trial.
@en
prefLabel
Effect of Fluorouracil, Leucov ...... ric Randomized Clinical Trial.
@en
P2093
P2860
P1433
P1476
Effect of Fluorouracil, Leucov ...... ric Randomized Clinical Trial.
@en
P2093
David S Shames
Dustin Smith
Florian Lordick
Ian McCaffery
Jean Marie Bruey
Manish A Shah
Maria Alsina
Stephen P Hack
P2860
P304
P356
10.1001/JAMAONCOL.2016.5580
P577
2016-12-01T00:00:00Z